Overview

Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

Status:
Completed
Trial end date:
2019-12-06
Target enrollment:
Participant gender:
Summary
In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients with gastrointestinal signs of GVHD that were treated with teduglutide.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Freiburg
Treatments:
Teduglutide